MONDAY, NOVEMBER 16, 2026 Tech news, minus the noise.
N News Cast
LATEST
Business

Oura Is Buying Counsel Health for $625 Million to Turn Your Ring Into a Doctor

Oura agreed to buy AI-native primary care startup Counsel Health for $625 million in cash. The deal pairs the smart ring's biometric data with medical AI and licensed physicians, and it follows a record quarter for Oura.

Oura Is Buying Counsel Health for $625 Million to Turn Your Ring Into a Doctor
Source: via Wikimedia Commons (CC BY 2.0)

From tracking your health to treating it

The Oura Counsel Health deal is the clearest sign yet that wearable companies want to stop being data collectors and start being healthcare providers. Oura, the maker of the smart ring, announced on November 10 that it has agreed to acquire Counsel Health, an AI-native primary care company, for $625 million in cash. The transaction is expected to close before the end of the calendar year, subject to customary closing conditions.

Counsel Health combines a chat-based medical AI with access to licensed, board-certified physicians. Members can ask health questions, get advice, and receive prescriptions or referrals without leaving the app. About 70 Counsel employees will join Oura, and Counsel co-founder and CEO Dr. Muthu Alagappan will become Oura's chief clinical AI officer. Counsel's physician network is made up of about 50 doctors, and the company plans to expand it.

The two companies are not strangers. Oura first integrated Counsel's service into its mobile app in June 2026, so the acquisition formalizes a relationship that already exists. The difference now is ownership: Oura is buying the doctors, the AI, and the clinical operation, not just licensing a chatbot.

Why the Oura Counsel Health deal happened now

Oura CEO Tom Hale said the combination would allow members to act on information about their physiology through services ranging from everyday medical questions to chronic care and referrals. In plain terms: the ring tells you something is wrong, and now there is a doctor in the same app to tell you what to do about it.

That closes a gap that has frustrated wearable owners for years. A smart ring can tell you your heart rate variability dropped, your temperature spiked, or your sleep was terrible. What it could not do, until now, was tell you whether any of that mattered, or what to do next. The usual answer was to show the data to your own doctor, who had never seen it before and had ten minutes to look at it. Oura's bet is that the company holding the data should also hold the clinical relationship.

The financial context makes the timing clear. Alongside the deal, Oura reported a record fiscal fourth quarter: revenue grew 153 percent year over year to $533 million for the quarter ended September 30, 2026. For fiscal 2026, revenue was approximately $1.75 billion, up 92 percent. Oura says it has more than six million members. Those numbers are preliminary and unaudited, but they explain the confidence: Oura can afford a $625 million acquisition because its core business is growing fast enough to pay for it.

There is also a defensive logic. Oura postponed a planned IPO of up to $2.2 billion just weeks before the announcement, citing uncertainty in the IPO market. A company that cannot go public needs another way to grow, and acquisitions are the obvious one. This is not Oura's first: Galen AI and Doublepoint AI were bought earlier in the year. Counsel Health is the biggest of the three, and the one that changes what the company is.

What Counsel Health actually is

Counsel Health was founded in 2023 by physician and AI researcher Muthu Alagappan. It describes itself as an AI-native primary care company serving health plans, health systems, digital health companies, employers, and consumers. Its medical AI handles the first conversation, and licensed physicians handle the judgment calls: prescriptions, referrals, and the cases where an AI should not be the one deciding.

Counsel had previously disclosed about $36 million in funding, including a $25 million Series A a year ago led by Andreessen Horowitz and GV. The $625 million price is roughly seventeen times that funding total, which tells you how much Oura values the clinical operation and the team, not just the technology. The company will keep offering its medical AI platform outside Oura's user base, through new and existing enterprise partners, so the acquisition is not a shutdown of Counsel's other business.

The service is not intended for emergencies, which still require calling 911. That disclaimer matters, because it draws the line between what the combined company will do and what it will not. It will answer health questions, monitor ongoing conditions, and connect members with doctors. It will not replace emergency care, and it should not be used as if it could.

The questions nobody has answered yet

Two questions will decide whether this deal is good for Oura members. The first is price. Oura has not said whether the new care features will be part of the existing subscription or a separate add-on. A ring that costs a few hundred dollars plus a subscription is already a premium product. Adding a doctor's visit to the bill, even a virtual one, changes the value calculation, and members will want to know what they are paying for.

The second is privacy. The reports reviewed so far do not say how users' biometric and health data will be handled or protected under the combined service. A ring that tracks your sleep, heart rate, and temperature already holds deeply personal data. Adding a medical AI and a physician network to the same company concentrates that data further. Oura will need to explain, clearly and soon, who can see what, and what happens to the data if a member leaves.

Those questions do not make the deal a bad one. They make it an incomplete one. The strategy is sound: wearables that only track are a commodity, and the companies that survive will be the ones that do something with the data. Oura just bought the most expensive possible version of doing something with it.

For the industry, the deal is part of a wider consolidation. The DoorDash Instacart acquisition showed the same pattern in food delivery, and the Siemens MERMEC acquisition showed it in rail tech: big companies buying their way into adjacent businesses rather than building from scratch. The Analog Devices Alif clearance showed the regulatory side of the same trend. Oura's move fits the pattern, with one difference: it is buying its way into healthcare, the industry where getting it wrong has the highest stakes. The ring is the easy part. The doctors are the hard part, and Oura just spent $625 million to own them.

AS
News Cast Editorial Team

We cover AI, gadgets, startups and security — original reporting and explainers, written by humans, for humans. Got a tip? Reach us via the contact page.